Lv2
158 积分 2022-12-29 加入
Overcoming EGFR-TKI resistance by targeting the tumor microenvironment
1天前
已完结
A phase 2/3 study of romiplostim N01 in chemotherapy-induced thrombocytopenia (CIT)
1个月前
已完结
Consensus on the lung cancer management after third-generation EGFR-TKI resistance
2个月前
已完结
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
2个月前
已完结
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer
2个月前
已完结
VP9-2021: ORIENT-31: Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy
3个月前
已完结
LBA58 Sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated non-squamous non-small cell lung cancer (EGFRm nsqNSCLC) who progressed on EGFR tyrosine-kinase inhibitors (TKIs) therapy: Second interim analysis of phase III ORIENT-31 study
3个月前
已完结
Consensus on the lung cancer management after third-generation EGFR-TKI resistance
3个月前
已完结
The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015
3个月前
已完结
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial
5个月前
已完结
皖公网安备34019202002308
